Last update Aug. 19, 2022

Nimodipine

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is a dihydropyridine calcium channel blocker with special action on cerebral blood vessels. It is used in the prevention and treatment of ischemic neurological deficits after subarachnoid hemorrhage due to intracranial aneurysm rupture. Oral or intravenous administration.

Excreted into breast milk in a non-significant amount. (Carcas 1996, Tonks 1995)

Because of pharmacokinetic data (high protein-binding capacity and low oral bioavailability) the observed low excretion into breast milk would be explained.

Nimodipine does not alter secretion of Prolactin. (Formisano 1991, Haitas 1986)

Several medical societies and expert authors consider the use of this medication possible during breastfeeding. (Hale, LactMed, Malachias 2016, Briggs 2015, Schaefer 2015)

Alternatives

We do not have alternatives for Nimodipine since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Nimodipine in other languages or writings:

Group

Nimodipine belongs to this group or family:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 16 (3 - 30) %
Molecular weight 418 daltons
Protein Binding 97 - 99 %
VD 0.94 l/Kg
pKa 16.96 -
Tmax 0.5 - 1 hours
1.1 - 1.7 hours
M/P ratio 0.06 - 0.3 -
Theoretical Dose 0.00024 mg/Kg/d
Relative Dose 0.001 - 0.1 %

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on March 17, 2022 Full text (link to original source)
  2. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/ 2006 - Consulted on March 15, 2022 Full text (link to original source)
  3. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source) Full text (in our servers)
  4. AEMPS. Nimodipino. Ficha técnica. 2016 Full text (in our servers)
  5. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, Third Edition. 2015
  6. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  7. Bayer. Nimodipine. Drug Summary. 2011 Full text (in our servers)
  8. Carcas AJ, Abad-Santos F, de Rosendo JM, Frias J. Nimodipine transfer into human breast milk and cerebrospinal fluid. Ann Pharmacother. 1996 Abstract
  9. Tonks AM. Nimodipine levels in breast milk. Aust N Z J Surg. 1995 Abstract
  10. Formisano R, Falaschi P, Cerbo R, Proietti A, Catarci T, D'Urso R, Roberti C, Aloise V, Chiarotti F, Agnoli A. Nimodipine in migraine: clinical efficacy and endocrinological effects. Eur J Clin Pharmacol. 1991 Abstract
  11. Haitas B, Joffe BI, Edelstein D, Panz V, Lamprey JM, Seftel HC. Calcium antagonists (nifedipine and nimodipine) and pituitary responses to thyrotropin releasing hormone stimulation. J Cardiovasc Pharmacol. 1986 Abstract

Total visits

26,551

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM